Biodelivery sciences international, inc. (BDSI)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Revenues:
Total Revenues

111,389

55,640

61,985

15,546

-

-

-

-

-

-

-

Cost of sales

21,590

15,783

19,496

11,258

-

-

-

-

-

-

-

Product sales

-

-

-

-

4,157

76

-

-

-

-

-

Product royalty revenues

-

-

-

-

1,406

3,407

1,773

1,083

2,716

1,884

2,844

Research revenue

-

-

-

-

-

-

-

13

227

726

-

Research and development reimbursements

-

-

-

-

909

12,712

2,783

-

-

-

-

Product royalties, related party

-

-

-

-

-

-

-

-

-

-

15

Research fees

-

-

-

-

-

-

-

-

-

-

177

Sponsored research revenue

-

-

-

-

-

-

-

-

-

244

-

Contract revenue

-

-

-

-

41,759

22,749

6,800

53,446

318

549

59,777

Total revenues

-

-

-

-

48,231

38,944

11,356

54,542

3,262

3,404

62,814

Cost of sales

-

-

-

-

8,101

4,939

2,082

1,910

1,756

839

2,043

Expenses:
Research and development

0

4,900

13,000

18,878

20,624

34,285

53,327

35,366

20,805

10,645

10,177

Related party research and development

-

-

-

-

-

-

-

-

-

-

143

Selling, general and administrative

86,063

58,602

58,869

49,345

54,685

38,460

12,349

-

7,608

7,913

8,399

Selling, general and administrative

-

-

-

-

-

-

-

10,205

-

-

-

Related party general and administrative, net

-

-

-

-

-

-

-

-

81

82

1,921

Impairment of intangible license

-

-

-

-

-

-

-

-

-

243

-

Total Expenses:

86,063

63,505

71,909

68,223

75,309

72,745

65,676

45,571

28,494

18,884

20,641

Income (loss) from operations

3,736

-23,648

-29,420

-63,935

-35,179

-38,740

-56,402

7,061

-26,987

-16,319

40,129

Interest expense

19,040

10,192

8,577

3,267

2,518

2,016

903

-

-

-

-

Bargain purchase gain

0

0

27,336

-

-

-

-

-

-

-

-

Derivative loss

-

-

-

-

-

13,167

-

-

-

-

-

Interest expense, net

-

-

-

-

-

-

-

281

188

133

35

Derivative (loss) gain

-

-

-

-

-

-

121

-5,594

3,463

3,126

-6,790

Other (expense) income, net

4

-14

-26

64

25

-295

-210

33

10

25

-15

Loss before income taxes

-15,300

-33,854

-10,687

-67,138

-37,672

-

-

-

-

-

-

Total nonoperating Income (Expense)

-

-

-

-

-

-

-

-5,280

3,662

3,286

-

(Loss) income before taxes

-

-

-

-

-

-

-

1,781

-23,325

-13,032

33,358

Income tax benefit (expense)

5

13

-15,972

-

0

-

-

129

-

0

312

Net (loss) income

-15,305

-33,867

5,285

-67,138

-37,672

-54,218

-57,394

-

-

-13,032

33,046

Beneficial conversion feature of convertible preferred stock

0

12,500

0

-

-

-

-

-

-

-

-

Net income (loss) attributable to common stockholders

-15,305

-46,367

5,285

-67,138

-

-

-

1,652

-23,325

-13,032

33,046

Basic:
Basic and diluted:
Weighted average common stock shares outstanding, basic and diluted

-

-

-

-

-

48,355

37,941

-

-

-

-

Weighted average common stock shares outstanding, basic (in shares)

83,213

63,165

55,355

53,679

52,384

-

-

30,546

28,322

23,150

20,224

Basic and diluted loss per share

-

-

-

-

-

-1.12

-1.51

-

-

-

-

Basic earnings (loss) per share (in usd per share)

-0.18

-0.73

0.10

-1.25

-0.72

-

-

0.05

-0.82

-0.56

1.63

Diluted:
Weighted average common stock shares outstanding, diluted (in shares)

83,213

63,165

56,402

53,679

52,384

-

-

30,689

28,322

23,150

21,499

Diluted earnings (loss) per share (in usd per share)

-0.18

-0.73

0.09

-1.25

-0.72

-

-

0.05

-0.82

-0.56

1.54

Product sales
Total Revenues

107,888

51,410

34,922

8,266

-

-

-

-

-

-

-

Product royalty revenues
Total Revenues

3,341

3,389

5,070

3,646

-

-

-

-

-

-

-

Research And Development Reimbursements
Net product sales

0

0

799

1,134

-

-

-

-

-

-

-

Contract revenues
Total Revenues

160

841

21,194

2,500

-

-

-

-

-

-

-